Navigation Links
Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
Date:3/23/2010

SOUTH SAN FRANCISCO, Calif., March 23 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that it has initiated its first in human Phase 1 trial in healthy volunteers of PRT062607, a novel, oral Syk-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In preclinical in vivo models of RA, PRT062607 was shown to reduce inflammation in a dose-dependent manner.

PRT062607 is Portola's lead compound discovered from an extensive kinase chemistry effort that has led to the development of potent, oral inhibitors of Spleen Tyrosine Kinase (Syk) and Janus Kinase (JAK).  Syk and JAK play key roles in signaling pathways that modulate inflammation and certain cancers.  PRT062607 has been shown to be a highly specific inhibitor of Syk in a broad panel of in vitro kinase and cellular assays.

"Because of its key role as a mediator in a number of important signaling pathways, specific, low-level Syk inhibition may be ideal for the management of chronic inflammatory diseases, such as RA, and may be better tolerated than less selective kinase inhibitors," said Daniel D. Gretler, M.D., chief medical officer of Portola.  "The initiation of the Phase 1 trial of PRT062607 is an important milestone toward our go
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
2. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
3. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
4. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
5. Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
6. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
7. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
9. Poniard Pharmaceuticals Announces $6.3 Million Financing
10. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
11. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013   RxAlly , a first-of-its-kind alliance ... the publication of a white paper entitled Personalized ... The white paper highlights an unprecedented solution for ... engagement to avert strains on the health care ... a range of individually-tailored, pharmacist-provided clinical and consultative ...
(Date:5/20/2013)... -- Volcano Corporation (NASDAQ: VOLC ) a leading ... to enhance the diagnosis and treatment of coronary and ... efforts to expand research and innovation surrounding its physiology ... ® (Instant Wave-Free Ratio™) 1 technologies, via ... 2013 in Paris . ...
(Date:5/20/2013)... Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Directors declared, at its meeting on May 16, 2013, ... for the third quarter of fiscal 2013.  The dividend ... of record on June 7, 2013. About ...
Breaking Medicine Technology:RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4Landauer, Inc. Declares Regular Cash Dividend 2
(Date:5/21/2013)... Beginning May 21st, 2013, DTP Sales ... 8000, the newest in digital recording technology, to the ... product for anyone looking to get the most from ... 8000 is expected to have revolutionary options and ... voice recorder features and highlights: , ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Tools4ever, the ... has made its Self Service Reset Password Management (SSRPM) ... employees can now use the service on mobile systems ... end users can easily reset their Windows passwords anywhere, ... of questions correctly, the user may then reset his ...
(Date:5/21/2013)... HealthDay Reporter , , MONDAY, May 20 ... millions of people with chronic obstructive pulmonary disease ... among older patients, a new large Canadian study ... age 65 who are prescribed long-acting bronchodilators -- ... as Serevent). Both medications are commonly used to ...
(Date:5/21/2013)... PHILADELPHIA The surgical management of non-small cell lung ... the race of the patient, according to a new ... I and Stage II NSCLC is surgery," said researcher ... in Omaha, Nebraska. "In our study of more than ... the years 2000 and 2010, we found statistically significant ...
(Date:5/21/2013)... 2013, PHILADELPHIA ─ A novel approach to obstructing ... of asthma has shown promise in a Phase ... , Their research will be presented at the ... simultaneously online in the New England Journal ... trial tested the efficacy and safety of the ...
Breaking Medicine News(10 mins):Health News:DTP Sales & Service Announces Upcoming Availability Of Philips Pocket Memo 8000 Series 2Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 2Health News:Certain COPD Meds Might Raise Heart Risks, Study Says 3Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3
... of the Board, SAN DIEGO, Aug. 30 ... board of directors has unanimously approved a,succession plan for ... T. Gallahue will be promoted to Chief Executive Officer ... will succeed Dr. Peter,C. Farrell, 65. As of January ...
... following is a,memorandum to editorial writers and columnists:, ... Communications,Director, SUBJECT: Katrina Storm Warning, On ... New Orleans,and the Gulf Coast are struggling to ... disasters in U.S. history. Disaster often strikes suddenly,and ...
... air pollution, aging are main causes of spread worldwide, ... There are more people around the world suffering from ... international team of researchers reports. , Worse yet, those ... continues to age, claims the study in the Sept. ...
... Aug. 30 Omnicell, Inc.,(Nasdaq: OMCL ) a ... and operational efficiency in healthcare,facilities, today announced that Randall ... president & CFO will present at the Thomas Weisel,Partners ... Mass.,on Wednesday, September 5, 2007 at 11:30 a.m. Eastern ...
... Aug. 30 The following was issued,today by Active ... Executive Director, Active Minds, Inc. WHAT: Ms. Malmon ... student advocacy, including depression and suicide Ms. Malmon ... is,nationally recognized for her unique peer-to-peer approach in addressing,the ...
... N.C., Aug. 30 Cogdell Spencer Inc.,(NYSE: ... acquired Summit,Professional Plaza I and II in Brunswick, ... building complex totals 97,472 square feet and is,98 ... new market and new client relationship,for Cogdell Spencer. ...
Cached Medicine News:Health News:ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008. 2Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 2Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 3Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 4Health News:Campaign for America's Future Memorandum: Katrina Storm Warning 5Health News:Prevalence of COPD Greater Than Thought 2Health News:Prevalence of COPD Greater Than Thought 3Health News:Omnicell to Present at Thomas Weisel Healthcare Conference 2007 2Health News:College Mental Health Expert and Sister of Student Who Died By Suicide Available to Discuss College Mental Health Issues 2Health News:Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: